CurrentRheuma — Inflammatory myopathies

Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease

2026-11-13T08:15:53.797Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2026.

Elevated lactate dehydrogenase and co-infection: predictors of rapidly progressive interstitial lung disease and fatal outcomes in anti-MDA5-positive dermatomyositis

2026-11-09T17:15:24.911Z

Cohort study · Clin Exp Rheumatol, 2025.

Normal Creatine Kinase in Idiopathic Inflammatory Myopathies: Disease Characteristics and Outcomes

2026-11-05T13:24:18.717Z

Secondary analysis · Joint Bone Spine, 2026.

Rituximab for the treatment of calcinosis in dermatomyositis: A case series and review of the literature

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Epidemiology, autoimmune overlap and in-hospital outcomes of idiopathic inflammatory myopathies in Spain, 1997–2024

2026-11-05T13:10:58.883Z

Cohort study · Rheumatology (Oxford), 2026.

Risk stratification of severe infections after remission induction therapy in idiopathic inflammatory myopathy: a multicentre MYKO study

2026-11-05T13:10:58.883Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2026.

Spatial transcriptomics in immune-mediated necrotising myopathy uncovers a specific necrotic signature related to immune-driven fibrosis

2026-11-05T13:10:58.883Z

Research article · Ann Rheum Dis, 2026.

Anti-MDA5-positive dermatomyositis and remission in a single referral centre population

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Clinical remission (off all immunosuppression >1 year while asymptomatic), median follow-up 3.5 years: Patients achieving clinical remission 9 (18%)

Application of logistic regression and machine learning methods for idiopathic inflammatory myopathies malignancy prediction

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2023. Malignancy prediction, LR model: AUC of ROC, LR, training set 0.900

Association of the serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Serum IgG glycan levels (lectin microarray and lectin blot): DM had significantly lower mannose and glucose glycan levels vs DC

Current status of clinical outcome measures in inclusion body myositis: a systematised review

2026-11-04T23:43:54.165Z

Research article · Clin Exp Rheumatol, 2022. Outcome measures used in IBM clinical studies: Observational studies 13

High prevalence of necrotising myopathy pattern in muscle biopsies of patients with anti-Jo-1 antisynthetase syndrome

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. Muscle biopsy pattern: Necrotising myopathy pattern 38.5%

In-patient comorbidities in inclusion body myositis: a United States national in-patient sample-based study

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Inpatient comorbidities (multivariable logistic regression) — IBM vs IIM: OR 3.03; aspiration pneumonia

Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2023. IIM incidence rate: COVID-19 18 (0.66 patients/month) · Pre-pandemic 16 (0.28 patients/month)

Increased serum levels of sCD40L were associated with rapidly progressive interstitial lung disease in idiopathic inflammatory myopathies

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Independent risk factors of short-term mortality in RPILD (multivariable Cox regression): Albumin<32.4 g/L: independent risk factor

Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Survival: Pre-IIT 8; deaths of 12 RP-ILD cases, median time to death 2.5 months; mean ferritin (ng/mL) 2,342 · IIT 2; deaths of 8 2; mean ferritin 3,558

Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Pulmonary lesions: ILD (various types) 14/33, 42.4%

Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-centre cohort

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2023. Survival rates, 5, 10, 15, 20 and 25 years: Survival at 5 years 89%

Potential role of type I interferon/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis

2026-11-04T23:43:54.165Z

Mechanistic study · Clin Exp Rheumatol, 2022. Serum IP-10 significantly higher in DM with anti-MDA5 antibodies than in those without, decreasing drastically upon treatment

Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Ig levels during RTX treatment: Low IgG (<700 mg/dl), proportion of patients 10%

The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients: a single centre experience

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2022. COVID-19 infection incidence, By June 1st, 2021: Incidence of COVID-19 infections in IIM cohort 34.7%

The role of magnetic resonance imaging in the diagnostic work-out of myopathies: differential diagnosis between inflammatory myopathies and muscular dystrophies

2026-11-04T23:43:54.165Z

Diagnostic or prognostic study · Clin Exp Rheumatol, 2022. Muscular MRI findings (oedema, atrophy, intramuscular adipose changes) — IIM vs MD; p<0.001; Oedema more prevalent in IIM, pelvis muscles

Transcranial direct current stimulation is safe and effective in autoimmune myopathies: a randomised, double-blind, sham-controlled trial

2026-11-04T23:43:54.165Z

Randomized controlled trial · Clin Exp Rheumatol, 2021. Efficacy: SF-36, timed up-and-go test, peak torque: Active tDCS: physical aspects of SF-36 at week 8, mean and better timed up-and-go test at each evaluation, peak torque of stimulated inferior limb extension improved significantly p<0.05

Two emerging phenotypes of atypical inclusion body myositis: illustrative cases

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2023. Atypical IBM phenotypes: Young-onset IBM, symptoms since early thirties 2

Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review

2026-11-04T23:43:54.165Z

Research article · Clin Exp Rheumatol, 2022. Improvement in refractory skin disease after JAKi: Adult DM 61; improved / with refractory skin disease 61 of 61 · JDM 57 (95%); improved / with refractory skin disease 57 of 60

Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis

2026-11-04T23:40:51.898Z

Case-control study · Scand J Rheumatol, 2021. Survival rate: PE 91% · Without PE 50%

A Systematic Review and Metaanalysis of Predictors of Mortality in Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. Mortality: Anti-MDA5 antibodies, OR for death 6.20 (95% CI 3.58-10.71)

Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody–Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Anti-Ro52+ vs Anti-Ro52−: RP-ILD rate (higher in anti-Ro52+); log-rank P < 0.001

Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies

2026-11-04T23:02:07.938Z

Cohort study · Semin Arthritis Rheum, 2023. FVC improvement >10%, 6 to 12 months: CYC 64% · non-CYC 32%

Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: International study from the OMERACT myositis working group

2026-11-04T23:02:07.938Z

Diagnostic or prognostic study · Semin Arthritis Rheum, 2022. Construct validity: a priori hypotheses met: A priori hypotheses met, all PROMIS instruments 10 out of 13

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Improvement after dose escalation of tofacitinib: Tofacitinib dose escalation 4

Immunoproteasome subunit β5i promotes perifascicular muscle atrophy in dermatomyositis by upregulating RIG-I

2026-11-04T22:58:59.711Z

Mechanistic study · RMD Open, 2023. β5i and RIG-I expression in DM muscle significantly increased and closely associated with muscle disease severity

Pain in autoimmune inflammatory myopathies: a scoping review

2026-11-04T22:58:59.711Z

Research article · RMD Open, 2023. Pain in adult AIM: Frequency of pain and/or myalgias 64% to 100%

Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study

2026-11-04T22:58:59.711Z

Cohort study · RMD Open, 2023. Mortality, 1 year: SPNM 34.8% · non-SPNM 7.3%

Long-term secular trends in dermatomyositis and polymyositis mortality in the USA from 1981 to 2020 according to underlying and multiple cause of death mortality data

2026-11-04T22:57:04.788Z

Cohort study · Arthritis Res Ther, 2023. APC of mortality, by joinpoint segment: DM, UCD: APC 1981-1982 to 1985-1986 - 6.7%

Cessation of Immunomodulatory Medication Use in Dermatomyositis: A Single‐Center Cohort Study

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2023. Discontinued all immunomodulatory medications: All DM patients 47 (19%)

Comparison of Patient‐Reported Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis

2026-11-04T22:50:06.138Z

Cross-sectional study · Arthritis Care Res (Hoboken), 2022. PROMIS fatigue, pain interference, upper extremity function, mobility, anxiety and depressive symptoms: CAT vs FSF mean scores: CAT and FSF mean scores did not significantly differ except in parent proxy anxiety and fatigue

Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort Study

2026-11-04T22:50:06.138Z

Cohort study · Arthritis Care Res (Hoboken), 2022. Incidence, prevalence and mortality of DM: Adjusted incidence of DM, per 100,000 person-years 1.1 (95% CI 0.7-1.5)

Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies

2026-11-04T22:45:44.055Z

Diagnostic or prognostic study · Rheumatology (Oxford), 2022. Diagnostic accuracy (ROC) distinguishing IIM from controls: ROC curves distinguished patients and controls based on ∑power Doppler (PD), ∑oedema, ∑atrophy and CRP

Adipose tissue distribution is associated with cardio-metabolic alterations in adult patients with juvenile-onset dermatomyositis

2026-11-04T22:45:44.055Z

Cross-sectional study · Rheumatology (Oxford), 2022. VAT: Patients exhibited a 2.4-fold increase in VAT compared with controls (P-values ≤ 0.05)

Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features

2026-11-04T22:45:44.055Z

Cross-sectional study · Rheumatology (Oxford), 2022. Anti-FHL1 autoantibodies present: Juvenile IIM 10.9% · Controls 1.1%

Evaluating the value of superoxide dismutase in anti-MDA5-positive dermatomyositis associated with interstitial lung disease

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. Serum SOD level: Serum SOD significantly lower in anti-MDA5-positive DM than controls

Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. Inactive disease, baseline vs last follow-up: Patients with inactive disease at baseline 10.3%

Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey

2026-11-04T22:45:44.055Z

Cross-sectional study · Rheumatology (Oxford), 2022. PROMIS PF-10a score, predicted mean (binomial regression model): IIM predicted mean 36.3 (95% CI 35.5, 37.1) · Non-IIM AIRD predicted mean 41.3 (95% CI 40.2, 42.5) · HCs predicted mean 46.2 (95% CI 45.8, 46.6)

Longitudinal changes in nailfold videocapillaroscopy findings differ by myositis-specific autoantibody in idiopathic inflammatory myopathy

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. Longitudinal change in NVC findings, baseline to after stabilization, after disease activity stabilization: Enlarged capillaries improved after stabilization in anti-MDA5 P < 0.0001

Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. Total improvement score, mean improvement, 6 and 12 months: Mean (SD) improvement in total improvement score at 6 months 44.5 (16)

Peripheral expansion of myeloid-derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies

2026-11-04T22:45:44.055Z

Cross-sectional study · Rheumatology (Oxford), 2022. MDSCs in IIM vs healthy donors: IIM patients had a peripheral expansion of PMN-MDSCs and M-MDSCs with an enhanced expression of arginase-1 and PD-L1

Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China

2026-11-04T22:45:44.055Z

Cohort study · Rheumatology (Oxford), 2022. RPILD occurring in the first 6 months after disease onset >90%

Work situation, work ability and expectation of returning to work in patients with systemic autoimmune myopathies

2026-11-04T22:45:44.055Z

Cross-sectional study · Rheumatology (Oxford), 2022. Work situation: Paid work 33 (44%) · Out of work 42 (56%)

Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial

2026-11-04T22:44:44.782Z

Randomized controlled trial · Lancet Rheumatol, 2023. Percent change in CK vs baseline, mean (SD), Week 8: Zilucoplan mean -9.86% ± 26.06 · Placebo mean -20.72% ± 31.22